Skip to content

Construction and Clinical Translation of a Dynamic Prediction Model Based on BMPs in First-Episode Schizophrenia

Construction and Clinical Translation of a Dynamic Prediction Model Based on BMPs in First-Episode Schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127216
Enrollment
Unknown
Registered
2026-06-26
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First-episode schizophrenia (acute phase), ICD-11 code 6A20.00

Interventions

Control Group:None

Sponsors

Nantong Fourth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient Group: 1. Meets the diagnostic criteria for schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); the diagnosis is independently assessed and confirmed by two qualified psychiatrists; 2. First episode of illness and has not received any psychotropic medication; 3. Aged 18–65 years; 4. No gender restriction, Han ethnicity; 5. Education level of primary school or above, capable of cooperating to complete neurocognitive function tests; 6. Positive and Negative Syndrome Scale (PANSS) score = 60; 7. The patient or their legal guardian voluntarily participates in the study and signs a written informed consent form. Control Group: 1. The control group consists of healthy individuals recruited to match the patient group in terms of age, gender, and education level.

Exclusion criteria

Exclusion criteria: 1.Substance dependence or abuse, or mental retardation. 2.Presence of severe neurological diseases, such as stroke, epilepsy, or brain inflammation, or other diseases that may affect central nervous system function. 3.Presence of severe physical diseases, such as endocrine disorders, cardiovascular diseases, or liver and kidney dysfunction. 4.Pregnant or lactating women. 5.Use of medications that may affect the immune system within 3 months before the study, such as glucocorticoids or immunosuppressants. 6.Patients receiving combined electroconvulsive therapy. 7.Unable to cooperate with or refuse to participate in this study.

Design outcomes

Primary

MeasureTime frame
Treatment response rate;Serum concentrations of BMP-2, BMP-9, and BMP-10;

Countries

China

Contacts

Public ContactYang Qun

Nantong Fourth People’s Hospital

yangqun1860@163.com+86 513 85606979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026